ADT Increases Risk for Fractures in Older Prostate Cancer Patients, Study Shows

ADT Increases Risk for Fractures in Older Prostate Cancer Patients, Study Shows
Elderly prostate cancer patients taking androgen deprivation therapy (ADT) have an increased risk for bone fractures compared to prostate cancer patients without ADT or men without prostate cancer, a study found. Doctors should be particularly aware of patients with high age, low body mass index (BMI), and a prior history of fractures or falls — deemed relevant risk factors for fractures. The study, "Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures—a study from the fractures and fall injuries in the elderly cohort (FRAILCO)," was published in the journal Osteoporosis International. Osteoporosis — a silent condition in which bones deteriorate or become brittle and fragile — significantly increases the risk of fractures, particularly in the hips, spine, and wrists. The condition mainly affects women, but men can also develop the condition — up to one in four men older than 50 will break a bone because of osteoporosis — and seem to have a higher risk of death after a fracture than do women. Studies have shown that prostate cancer patients receiving ADT seem to have a particularly high risk of osteoporosis and fractures. ADT works by reducing the levels of testosterone, which fuels prostate cancer growth, but the approach also seems to cause reduced bone density and bone fragility. While this association has been described more than 20 years ago, and subsequently confirmed in other studies, no large studies existed comparing the incidence of fractures in prostate cancer patients on ADT versus men without the condit
Subscribe or to access all post and page content.

Tagged , , , , , , .

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

Leave a Comment

Your email address will not be published. Required fields are marked *